CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.
The data, presented at ASCO Annual Meeting, also showed half of the individuals enrolled have sustained a clinical complete response for at least 1 year.
“We are incredibly excited about the results,” Andrea Cercek, MD, gastrointestinal oncologist, section head of colorectal cancer and co-director of the Center for Young Onset Colorectal and Gastrointestinal